Table 3.
Sensitivity analysis.
| Sensitivity analysis 1a | Sensitivity analysis 2b | |||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| TyG | ||||
| Q1 | 1 (Reference) | / | 1 (Reference) | / |
| Q2 | 0.96 (0.76–1.21) | 0.73 | 0.98 (0.76–1.26) | 0.88 |
| Q3 | 1.14 (0.90–1.44) | 0.26 | 1.06 (0.82–1.38) | 0.65 |
| Q4 | 1.79 (1.39–2.3) | < 0.01 | 1.66 (1.25–2.19) | < 0.01 |
| Per 1 SD increase | 1.30 (1.19–1.43) | < 0.01 | 1.26 (1.13–1.39) | < 0.01 |
| TyG-BMI | ||||
| Q1 | 1 (Reference) | / | 1 (Reference) | / |
| Q2 | 1.42 (1.10–1.83) | 0.01 | 1.51 (1.14–2.01) | < 0.01 |
| Q3 | 1.88 (1.44–2.45) | < 0.01 | 1.89 (1.41–2.54) | < 0.01 |
| Q4 | 3.24 (2.46–4.27) | < 0.01 | 3.05 (2.24–4.15) | < 0.01 |
| Per 1 SD increase | 1.55 (1.43–1.68) | < 0.01 | 1.54 (1.40–1.69) | < 0.01 |
| TyG-WC | ||||
| Q1 | 1 (Reference) | / | 1 (Reference) | / |
| Q2 | 1.61 (1.25–2.08) | < 0.01 | 1.58 (1.20–2.09) | < 0.01 |
| Q3 | 1.78 (1.37–2.33) | < 0.01 | 1.58 (1.18–2.13) | < 0.01 |
| Q4 | 3.19 (2.42–4.20) | < 0.01 | 2.99 (2.21–4.05) | < 0.01 |
| Per 1 SD increase | 1.57 (1.44–1.70) | < 0.01 | 1.56 (1.41–1.71) | < 0.01 |
| TyG-WHtR | ||||
| Q1 | 1 (Reference) | / | 1 (Reference) | / |
| Q2 | 1.31 (1.02–1.69) | 0.04 | 1.24 (0.94–1.63) | 0.14 |
| Q3 | 1.75 (1.34–2.27) | < 0.01 | 1.60 (1.19–2.13) | < 0.01 |
| Q4 | 3.19 (2.44–4.17) | < 0.01 | 2.87 (2.13–3.87) | < 0.01 |
| Per 1 SD increase | 1.61 (1.48–1.75) | < 0.01 | 1.60 (1.45–1.76) | < 0.01 |
All models adjusted for age, race, income, smoking status, and menopause status, low-density lipoprotein, high-density lipoprotein, C-reactive protein, estradiol, and follicle-stimulating hormone.
aAnalysis was performed by including individuals with age ≤ 80.
bAnalysis was performed by using a stricter definition of hypertension.
cAnalysis was performed by excluding incident CMD within 2 years of follow-up.
Abbreviation: HR, hazard ratio; CI, confidence interval, TyG, triglyceride-glucose index, BMI, body mass index, WC, waist circumference. WHtR, waist-to-height ratio.